Literature DB >> 23959040

[Current status and problems of the entirely subcutaneous ICD (S-ICD®)].

F Reinke1, A Löher, J Köbe, L Eckardt.   

Abstract

Prevention of sudden cardiac death is one of the most important tasks of cardiology. Transvenous ICD-systems have impressively proven their effectiveness in numerous randomized trials. Transvenous systems have their limitations due to frequent long-term lead complications. Having been available for a few years, the entirely subcutaneous ICD-system (S-ICD®, Boston Scientific, USA, former Cameron Health, USA) seems to be a promising alternative despite the lack of prospective data. The implantation of the SICD® can be performed easily; lead complications are rare because of the totally subcutaneous implantation. The detection and therapy of life-threatening tachyarrhythmias seems to be safe, although inappropriate therapies are a common problem in cases of insufficient ECG screening. S-ICD® is no alternative to the transvenous system due to limited programming options and the lack of stimulation, but it is an interesting supplement of ICD therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23959040     DOI: 10.1007/s00399-013-0277-3

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  28 in total

1.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

Review 2.  ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary.

Authors:  Andrew E Epstein; John P Dimarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney
Journal:  Heart Rhythm       Date:  2008-05-19       Impact factor: 6.343

3.  Performance and survival of transvenous defibrillation leads: need for a European data registry.

Authors:  Andreas Goette; Francesco Cantu; Lieselot van Erven; Peter Geelen; Franck Halimi; Jose L Merino; John M Morgan
Journal:  Europace       Date:  2008-11-11       Impact factor: 5.214

4.  Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients.

Authors:  Peter Alter; Stefan Waldhans; Eveline Plachta; Rainer Moosdorf; Wolfram Grimm
Journal:  Pacing Clin Electrophysiol       Date:  2005-09       Impact factor: 1.976

5.  Mortality and cost associated with cardiovascular implantable electronic device infections.

Authors:  Muhammad R Sohail; Charles A Henrikson; Mary Jo Braid-Forbes; Kevin F Forbes; Daniel J Lerner
Journal:  Arch Intern Med       Date:  2011-09-12

6.  [Totally subcutaneous cardioverter-defibrillator (S-ICD®) : recent experience and future perspectives].

Authors:  J Köbe; S Zumhagen; F Reinke; E Schulze-Bahr; L Eckardt
Journal:  Herz       Date:  2011-10       Impact factor: 1.443

7.  Totally subcutaneous implantable cardioverter defibrillator with an alternative, right parasternal, electrode placement.

Authors:  Sven Zumhagen; Andrew A Grace; Stephen O'Connor; Andreas Löher; Julia Köbe; Lars Eckardt; Eric Schulze-Bahr
Journal:  Pacing Clin Electrophysiol       Date:  2011-03-14       Impact factor: 1.976

8.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

9.  The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.

Authors:  Louise R A Olde Nordkamp; Lara Dabiri Abkenari; Lucas V A Boersma; Alexander H Maass; Joris R de Groot; Antonie J H H M van Oostrom; Dominic A M J Theuns; Luc J L M Jordaens; Arthur A M Wilde; Reinoud E Knops
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

10.  Implantable cardioverter-defibrillator therapy in the absence of significant symptoms. Rhythm diagnosis and management aided by stored electrogram analysis.

Authors:  B G Hook; D J Callans; R B Kleiman; B T Flores; F E Marchlinski
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more
  2 in total

Review 1.  [Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death].

Authors:  L Eckardt; T Deneke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09

2.  [Completely subcutaneous implantable cardioverter defibrillator: Care of S-ICD wearers during childbirth].

Authors:  C Strewe; S Fichtner
Journal:  Anaesthesist       Date:  2015-09-04       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.